Full-Time

Software Engineer

Roche

Roche

1-10 employees

Global pharmaceuticals and diagnostics company

No salary listed

Madrid, Spain

In Person

Category
Software Engineering (1)
Required Skills
LLM
Streamlit
Kubernetes
Python
Atlassian
Java
Infrastructure as Code (IaC)
Cybersecurity
JIRA
Confluence
Web Development
DevOps
Helm

Get referred to Roche

See people who can refer or advise you

Requirements
  • Proven track record in an Engineer or DevOps/Platform Specialist role with solid hands-on delivery experience.
  • Proven track record managing enterprise-scale Atlassian installations, including Jira, Confluence, and ELM tools, supporting tens of thousands of active users.
  • Strong experience handling escalated L2/L3 support for enterprise digital tools and platforms.
  • Experience working with internal teams and external vendors or contractors.
  • Experience acting as a liaison between business end-users, software compliance teams, and Product Owners.
  • Proven experience driving small to medium initiatives.
  • Strong proficiency in at least one of Java full-stack development, DevOps practices including continuous integration and continuous delivery and infrastructure as code, or SaaS platform administration.
  • Hands-on Cloud and on-premises Administrator experience across the Atlassian ecosystem, including Jira Cloud, Confluence, plugins, API integrations, advanced site administration, permission schemes, workflow configuration, and marketplace app management.
  • Proficiency in Python for automation, scripting, and integrating AI-driven or AI-capable capabilities into workflows and support processes.
  • Capability across the full support spectrum, including reading log files, performing system audits, and writing code or scripts for Atlassian customization and API integrations.
  • Experience building internal Python web applications such as Streamlit applications that consume Jira API endpoints to optimize team workflows, sprint tracking, ideas, and dashboards.
  • Experience with deployment pipelines using ArgoCD and Helm to provision, synchronize, and scale enterprise Kubernetes pod instances with automated rollbacks.
  • Experience integrating Pytest and InSpec into continuous integration and continuous delivery pipelines for automated unit and integration testing and infrastructure-as-code compliance checks.
  • Expertise in one or more technology areas and the ability to select and apply appropriate technologies to solve complex problems.
  • Understanding of software operations, including performance tuning and scalability.
  • Knowledge of software development tooling and the ability to suggest adoption and improve developer productivity and experience.
  • Working knowledge of regulated and compliance best practices and the ability to ensure software solutions comply with security standards.
  • Ability to design and improve the software delivery process from code to production using and promoting best practices.
  • Understanding of cybersecurity and secure software development practices.
  • Ability to identify and proactively address technical debt, performance bottlenecks, and architectural challenges.
  • Understanding of software quality management and metrics.
  • Ability to plan and estimate work for small to medium tasks.
  • Advanced English proficiency.
  • Ability to communicate complex technical requirements clearly to non-technical stakeholders and tool owners.
Responsibilities
  • Take ownership of tasks and topics in the grey zone and drive small to medium initiatives.
  • Provide hands-on expertise in Java full-stack development, DevOps, infrastructure as code, or application and application infrastructure support.
  • Administer the Atlassian Suite in Cloud and on-premises environments, including platform stability, configurations, custom workflows, and integrations.
  • Handle escalated tickets and issues that previous support tiers cannot resolve, driving complex troubleshooting to resolution.
  • Use Python and AI or generative-AI-capable tools, including automation scripts, to streamline workflows, optimize ticket resolution, and automate repetitive platform operations and user experiences.
  • Engage end-users to gather, analyze, and translate feature requests into structured implementation plans for Product Owners and tool owners.
  • Provide end-to-end technical ownership, including deep troubleshooting, server-log and audit-log analysis, system-performance analysis, custom coding, and script-level changes.
  • Introduce, test, and roll out updates and improvements to the Atlassian product suite.
  • Support the enterprise migration from Jira Data Center on-premises to Jira Cloud while ensuring data integrity, compliance, and operational continuity.
  • Champion quality standards and drive adoption of standardized workflows and validation practices across teams.
  • Foster collaboration, knowledge sharing, and peer support within the team.
  • Prioritize and communicate effectively with stakeholders while maintaining a broader view of technical components and organizational strategy.
  • Align development plans with global strategy and contribute to initiatives beyond regular project scope.
  • Operate at the Product/Site level.
  • Formulate and implement technical strategies aligned with organizational objectives while improving creativity, innovation, and engineering quality.
Desired Qualifications
  • Hands-on experience with Data Center to Cloud migrations for Atlassian or enterprise tools.
  • Exposure to or understanding of GxP validation, regulatory compliance, and software quality management practices in a regulated environment.
  • Any language in addition to advanced English proficiency.

Roche is a global leader in pharmaceuticals and diagnostics. It develops medicines and diagnostic tools that help detect, monitor, and treat diseases, using research and biotechnology to drive new therapies and tests. Roche combines drug development with in-house diagnostic products to support personalized medicine, where treatments are tailored to individual patients based on test results. Its approach differs from many peers by integrating drug discovery with diagnostic capabilities and by expanding its research through strategic acquisitions (like Genentech) to strengthen its biotechnology and R&D capabilities. The company’s goal is to improve patient outcomes and healthcare worldwide by delivering reliable medicines, accurate diagnostic tests, and data-driven care.

Company Size

1-10

Company Stage

IPO

Headquarters

Basel, Switzerland

Founded

1896

Get referred to Roche

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • H1 2026 sales rose 6% CER, with core operating profit up 10%.
  • FDA cleared cobas BV/CV and PTEN assays in July 2026, expanding diagnostics revenue.
  • CHMP recommended Susvimo in July 2026, unlocking a differentiated EU eye-care launch.

What critics are saying

  • Genentech sued Biocon July 30, 2026 over Perjeta biosimilar, signaling franchise erosion.
  • Roche faces CHF0.6 billion 2026 loss-of-exclusivity pressure, crushing slower launches.
  • Kadcyla and Ocrevus expiration timelines threaten Roche’s oncology and immunology cash engine.

What makes Roche unique

  • Roche uniquely pairs blockbuster medicines with diagnostics, selling tests alongside therapies worldwide.
  • AXELIOS 1 and PathAI deepen Roche’s moat in sequencing and AI pathology.
  • Susvimo and cobas BV/CV show Roche turns specialty science into practical platform products.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company News

PR Newswire
Aug 6th, 2026
Roche expands cyclospora testing portfolio with three new assays for US public health labs

Roche has expanded its cyclospora testing portfolio with two new research-use-only molecular PCR tests to support U.S. public health response efforts. The LightMix Modular Cyclospora assay specifically detects cyclospora, whilst the LightMix OneTube Gastro Para 2 assay detects multiple parasites including Entamoeba histolytica, Giardia, and Cyclospora cayetanensis. Both tests work with LightCycler 480 and LightCycler PRO instruments. They complement an existing assay compatible with cobas 5800, 6800, and 8800 systems. The portfolio offers flexible testing options with one, three, or six targets. Roche acquired TIB MOLBIOL in December 2021 to expand its PCR-test capabilities for emerging infectious diseases. The company's testing infrastructure includes assays for hepatitis, HIV, respiratory illnesses, and vector-borne diseases.

PR Newswire
Jul 24th, 2026
Roche receives FDA clearance for cobas BV/CV assay for fast vaginitis diagnosis

Roche has received FDA 510(k) clearance for its cobas BV/CV assay, a molecular diagnostic test that detects bacterial vaginosis and Candida vaginitis from a single vaginal swab sample. The PCR-based test aims to improve diagnostic accuracy compared to traditional methods like microscopy and pH testing, which have misdiagnosis rates approaching 50%. Bacterial vaginosis affects approximately 27% of women of reproductive age in North America, whilst up to 75% of women experience Candida vaginitis at least once in their lifetime. The assay uses real-time PCR technology to identify specific bacteria and yeast responsible for these conditions. The test expands Roche's sexual health testing menu on its cobas 6800/8800 systems, enabling comprehensive testing for multiple conditions from a single sample. Commercial launch is expected later this year.

Yahoo Finance
Jul 24th, 2026
Roche's Susvimo receives EU approval recommendation as first continuous nAMD treatment requiring just two refills per year

Roche's Susvimo has received a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use for treating neovascular age-related macular degeneration (nAMD). Susvimo is the first continuous delivery treatment that offers an alternative to standard eye injections for nAMD, requiring only two refills per year through the Contivue refillable implant. The recommendation is based on data from the LADDER, Archway and Portal studies, which showed Susvimo maintained vision equivalent to monthly intravitreal ranibizumab injections, with data supporting vision maintenance up to seven years. Approximately 95% of patients treated with Susvimo required no supplemental treatment. nAMD is a leading cause of blindness in people over 60 and affects 1.7 million in the EU. A final decision is expected from the European Commission soon.

Yahoo Finance
Jul 23rd, 2026
Roche sales grow 6% at constant exchange rates in H1 2026, led by Xolair and Hemlibra

Roche reported 6% sales growth at constant exchange rates in the first half of 2026, though this translated to a 2% decline in Swiss francs due to currency appreciation. The Swiss pharmaceutical and diagnostics company's performance was driven by strong demand for its innovative medicines and diagnostic products. The Pharmaceuticals Division grew 6% at constant exchange rates, led by Xolair, Hemlibra, Ocrevus, Phesgo, and Vabysmo. The Diagnostics Division increased 3% at constant exchange rates, driven by immunodiagnostic and clinical chemistry products. Core operating profit rose 10% at constant exchange rates. Core earnings per share grew 9% at constant exchange rates but fell 2% in Swiss francs. Key developments included multiple US priority reviews for drug candidates and positive phase III trial data. Roche also launched its Axelios 1 sequencing platform and announced an agreement to acquire PathAI. The company confirmed its 2026 outlook, expecting mid-single-digit sales growth at constant exchange rates.

Yahoo Finance
Jul 23rd, 2026
Roche appoints Dan Malarek to lead North America diagnostics business

Roche has appointed Dan Malarek as President and CEO of Roche Diagnostics North America. The leadership change affects a key operating segment within the Swiss healthcare company's business. Malarek previously led Foundation Medicine, a Roche affiliate focused on precision medicine and genomic insights. His background ties directly into themes shaping modern diagnostics use in healthcare. The diagnostics arm is central to how Roche supports hospitals, laboratories, and clinicians with testing platforms and data-driven tools. Areas such as test menu development, data integration with pharmaceuticals, and health system partnerships are potential focus points under the new leadership. Roche shares currently trade at CHF332.4, approximately 8% below the CHF359.2 analyst consensus target.